XTX Topco Ltd Invests $31,000 in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

XTX Topco Ltd bought a new stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 35,553 shares of the company’s stock, valued at approximately $31,000.

A number of other institutional investors also recently modified their holdings of NAUT. Sentinel Trust Co. LBA raised its position in Nautilus Biotechnology by 9.8% in the 1st quarter. Sentinel Trust Co. LBA now owns 280,000 shares of the company’s stock valued at $241,000 after buying an additional 25,000 shares during the last quarter. Clarius Group LLC raised its position in Nautilus Biotechnology by 36.1% in the 1st quarter. Clarius Group LLC now owns 866,586 shares of the company’s stock valued at $746,000 after buying an additional 230,054 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Nautilus Biotechnology in the 4th quarter valued at $44,000. Wexford Capital LP raised its position in Nautilus Biotechnology by 42.4% in the 4th quarter. Wexford Capital LP now owns 325,239 shares of the company’s stock valued at $546,000 after buying an additional 96,889 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Nautilus Biotechnology in the 4th quarter valued at $63,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Trading Down 1.3%

NASDAQ NAUT opened at $0.71 on Friday. The firm has a market capitalization of $90.01 million, a P/E ratio of -1.37 and a beta of 1.42. The business has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $0.93. Nautilus Biotechnology, Inc. has a 12 month low of $0.66 and a 12 month high of $3.09.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. As a group, sell-side analysts predict that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current fiscal year.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.